NEW YORK--(BUSINESS WIRE)--BTIG, LLC announced today that Thomas Shrader, PhD, CFA, has joined the firm as a Managing Director to provide specialized biotechnology equity research. Based in New York, he will report into David Lenchus, Director of Research at BTIG.
Dr. Shrader will play a pivotal role in the expansion of the firm’s biotechnology research coverage. His expertise spans oncology, immunology, metabolics and neuroscience. With an established and growing presence within the biotechnology vertical, BTIG continues to strategically invest in talent across healthcare research, banking and trading.
“We are thrilled to welcome Tom to BTIG’s Research and Strategy team to bolster our biotechnology research effort,” said Mr. Lenchus. “As an accomplished healthcare research analyst, capital markets professional and academic, he will provide an insightful research product that will enlighten our clients and strengthen our highly responsive biotechnology research platform.”
Dr. Shrader has more than 20 years of biotechnology equity research experience. Prior to BTIG, he was the Vice President of Strategy and Communications at Intrexon Corporation. Previously, Dr. Shrader was a Biotechnology Research Analyst at Stifel and Bank of Montreal Capital Markets. He was also the Director of Strategic Corporate Partnerships at Yale University, and a Biochemistry faculty member at the Albert Einstein College of Medicine. Dr. Shrader earned a BA from Johns Hopkins University, a PhD from Yale University and was a Helen Hay Whitney Fellow at the Massachusetts Institute of Technology. He is also a CFA charterholder.
BTIG Research and Strategy provides comprehensive fundamental research reports and in-depth industry and company observations for clients. Its sector focus includes consumer, energy, financials, healthcare, real estate, shipping, and technology, media and telecommunications.
For access to BTIG insights, visit www.btigresearch.com.
BTIG is a global financial services firm specializing in institutional trading, investment banking, research and related brokerage services. With an extensive global footprint and more than 560 employees, BTIG, LLC and its affiliates operate out of 17 cities throughout the U.S., and in Europe, Asia and Australia. BTIG offers execution, expertise and insights for equities, equity derivatives, ETFs and fixed income, currency and commodities (futures, commodities, foreign exchange, interest rates, credit, and convertible and preferred securities). The firm’s core capabilities include global execution, portfolio, electronic and outsource trading, transition management, investment banking, prime brokerage, capital introduction, corporate access, research and strategy, commission management and more.
To learn more about BTIG, visit www.btig.com.